To Dr. Long, an epidemiologist, there has been very little high quality perspective research on NAFLD/NASH prevalence. She discusses why she considers the study a methodological advantage. She and Roger Green agree that the conventional wisdom, which posits a 25% incidence of NAFLD and that 25% of NAFLD patients have NASH, is probably far too low. Instead, they note, a more realistic NAFLD estimate might be 37% NAFLD and a more realistic NASH estimate might be 14%. This suggests a far greater need to screen quickly and aggressively across most patient segments. At that point, Louise Campbell joins the conversation to suggest a strategy to screen faster and more efficiently. All things considered, this conversation increases the salience of diagnosing and treating Fatty Liver disease and some ways to find patients.